Tags

Type your tag names separated by a space and hit enter

Tumoral versus non-tumoral hyperprolactinemia in children and adolescents: possible usefulness of the domperidone test.
J Pediatr Endocrinol Metab. 2003 Feb; 16(2):163-7.JP

Abstract

The aim of this study was to evaluate the usefulness of the domperidone test for the difficult diagnosis between functional and tumoral hyperprolactinemia. We evaluated 36 patients, aged 5-18 years, 14 (12 F, 2 M) with hyperprolactinemia (non-tumoral: 10; pituitary adenoma: 4) and 22 individuals as a control group (prepubertal: 5 F, 8 M; pubertal: 4 F, 5 M). Basal prolactin (PRL) (IRMA-DPC), T4 and TSH and PRL 30 min post-domperidone (0.2 mg/kg b. wt i.v.) were measured. Non-tumoral hyperprolactinemic females showed basal PRL: 45 (29-80) (median and range) ng/ml; post-domperidone: 208 (116-290) ng/ml; delta PRL (PRL 30' - PRL 0'): 167 (77-252) ng/ml; and PRL ratio (PRL 30'/PRL 0'): 3.9 (2.3-7.6). Females with pituitary adenoma showed basal PRL: 129 (125-660) ng/ml; post-domperidone: 202 (150-535) ng/ml; delta PRL: 73 (25-135) ng/ml; and ratio: 1.2 (0.8-1.6). Two males, one with a non-tumoral hyperprolactinemia and the other one with a pituitary adenoma, presented, respectively, PRL 0':45, 160; PRL 30':130, 173; delta: 85, 13; ratio: 2.9, 1.1. All non-tumoral patients showed a PRL ratio (30'/0') > 2.3, while no patient with pituitary adenoma had a ratio > 1.6.

CONCLUSIONS

PRL response to domperidone allowed us to characterize hyperprolactinemias, although the presence of a blunted response should be confirmed in a larger number of patients with tumors with 'low' PRL levels (dependence on etiology or basal PRL level?).

Authors+Show Affiliations

Endocrinology Unit, Medicine Department, Hospital T. Alvarez, Buenos Aires, Argentina. hugofideleff@arnet.com.arNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article

Language

eng

PubMed ID

12713252

Citation

Fideleff, Hugo L., et al. "Tumoral Versus Non-tumoral Hyperprolactinemia in Children and Adolescents: Possible Usefulness of the Domperidone Test." Journal of Pediatric Endocrinology & Metabolism : JPEM, vol. 16, no. 2, 2003, pp. 163-7.
Fideleff HL, Azaretzky M, Boquete HR, et al. Tumoral versus non-tumoral hyperprolactinemia in children and adolescents: possible usefulness of the domperidone test. J Pediatr Endocrinol Metab. 2003;16(2):163-7.
Fideleff, H. L., Azaretzky, M., Boquete, H. R., Pujol, A. B., Honfi, M., Suárez, M. G., Fideleff, G., & Giaccio, A. V. (2003). Tumoral versus non-tumoral hyperprolactinemia in children and adolescents: possible usefulness of the domperidone test. Journal of Pediatric Endocrinology & Metabolism : JPEM, 16(2), 163-7.
Fideleff HL, et al. Tumoral Versus Non-tumoral Hyperprolactinemia in Children and Adolescents: Possible Usefulness of the Domperidone Test. J Pediatr Endocrinol Metab. 2003;16(2):163-7. PubMed PMID: 12713252.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Tumoral versus non-tumoral hyperprolactinemia in children and adolescents: possible usefulness of the domperidone test. AU - Fideleff,Hugo L, AU - Azaretzky,Miriam, AU - Boquete,Hugo R, AU - Pujol,Andrea B, AU - Honfi,Margarita, AU - Suárez,Martha G, AU - Fideleff,Gabriel, AU - Giaccio,Ana V, PY - 2003/4/26/pubmed PY - 2003/9/16/medline PY - 2003/4/26/entrez SP - 163 EP - 7 JF - Journal of pediatric endocrinology & metabolism : JPEM JO - J Pediatr Endocrinol Metab VL - 16 IS - 2 N2 - UNLABELLED: The aim of this study was to evaluate the usefulness of the domperidone test for the difficult diagnosis between functional and tumoral hyperprolactinemia. We evaluated 36 patients, aged 5-18 years, 14 (12 F, 2 M) with hyperprolactinemia (non-tumoral: 10; pituitary adenoma: 4) and 22 individuals as a control group (prepubertal: 5 F, 8 M; pubertal: 4 F, 5 M). Basal prolactin (PRL) (IRMA-DPC), T4 and TSH and PRL 30 min post-domperidone (0.2 mg/kg b. wt i.v.) were measured. Non-tumoral hyperprolactinemic females showed basal PRL: 45 (29-80) (median and range) ng/ml; post-domperidone: 208 (116-290) ng/ml; delta PRL (PRL 30' - PRL 0'): 167 (77-252) ng/ml; and PRL ratio (PRL 30'/PRL 0'): 3.9 (2.3-7.6). Females with pituitary adenoma showed basal PRL: 129 (125-660) ng/ml; post-domperidone: 202 (150-535) ng/ml; delta PRL: 73 (25-135) ng/ml; and ratio: 1.2 (0.8-1.6). Two males, one with a non-tumoral hyperprolactinemia and the other one with a pituitary adenoma, presented, respectively, PRL 0':45, 160; PRL 30':130, 173; delta: 85, 13; ratio: 2.9, 1.1. All non-tumoral patients showed a PRL ratio (30'/0') > 2.3, while no patient with pituitary adenoma had a ratio > 1.6. CONCLUSIONS: PRL response to domperidone allowed us to characterize hyperprolactinemias, although the presence of a blunted response should be confirmed in a larger number of patients with tumors with 'low' PRL levels (dependence on etiology or basal PRL level?). SN - 0334-018X UR - https://www.unboundmedicine.com/medline/citation/12713252/Tumoral_versus_non_tumoral_hyperprolactinemia_in_children_and_adolescents:_possible_usefulness_of_the_domperidone_test_ L2 - https://www.degruyter.com/doi/10.1515/jpem.2003.16.2.163 DB - PRIME DP - Unbound Medicine ER -